Literature DB >> 32439845

In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study.

Masamichi Yokokura1, Kiyokazu Takebasashi1, Akiyo Takao2, Kyoko Nakaizumi1, Etsuji Yoshikawa3, Masami Futatsubashi4,5, Katsuaki Suzuki6, Kazuhiko Nakamura7, Hidenori Yamasue1, Yasuomi Ouchi8.   

Abstract

Alterations in the cortical dopamine system and microglial activation have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD), one of neurodevelopmental disorders that can be conventionally treated with a dopamine enhancer (methylphenidate) albeit unsatisfactorily. Here, we investigated the contributions of the dopamine D1 receptor (D1R) and activated microglia and their interactions to the clinical severities in ADHD individuals using positron emission tomography (PET). Twenty-four psychotropic-naïve ADHD individuals and 24 age- and sex-matched typically developing (TD) subjects underwent PET measurements with [11C]SCH23390 for the D1R and [11C](R)PK11195 for activated microglia as well as assessments of clinical symptoms and cognitive functions. The ADHD individuals showed decreased D1R in the anterior cingulate cortex (ACC) and increased activated microglia in the dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC) compared with the TD subjects. The decreased D1R in the ACC was associated with severe hyperactivity in the participants with ADHD. Microglial activation in the DLPFC were associated with deficits in processing speed and attentional ability, and that in the OFC was correlated with lower processing speed in the ADHD individuals. Furthermore, positive correlations between the D1R and activated microglia in both the DLPFC and the OFC were found to be significantly specific to the ADHD group and not to the TD group. The current findings suggest that microglial activation and the D1R reduction as well as their aberrant interactions underpin the neurophysiological mechanism of ADHD and indicate these biomolecular changes as a novel therapeutic target.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32439845     DOI: 10.1038/s41380-020-0784-7

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  71 in total

Review 1.  Role of dopamine receptors in ADHD: a systematic meta-analysis.

Authors:  Jing Wu; Haifan Xiao; Hongjuan Sun; Li Zou; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

2.  Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.

Authors:  Michael B Lensing; Pål Zeiner; Leiv Sandvik; Stein Opjordsmoen
Journal:  J Clin Psychiatry       Date:  2013-01       Impact factor: 4.384

3.  Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.

Authors:  Nao J Gamo; Min Wang; Amy F T Arnsten
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-09-01       Impact factor: 8.829

4.  In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors.

Authors:  Benjamin Gronier
Journal:  Eur Neuropsychopharmacol       Date:  2010-12-13       Impact factor: 4.600

5.  Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder.

Authors:  V L Misener; P Luca; O Azeke; J Crosbie; I Waldman; R Tannock; W Roberts; M Malone; R Schachar; A Ickowicz; J L Kennedy; C L Barr
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

Review 6.  Candidate gene studies of ADHD: a meta-analytic review.

Authors:  Ian R Gizer; Courtney Ficks; Irwin D Waldman
Journal:  Hum Genet       Date:  2009-06-09       Impact factor: 4.132

7.  The role of dopamine D₁ and D₂ receptors in adolescent methylphenidate conditioned place preference: sex differences and brain-derived neurotrophic factor.

Authors:  Elizabeth D Cummins; Stephen B Griffin; Chase M Duty; Daniel J Peterson; Katherine C Burgess; Russell W Brown
Journal:  Dev Neurosci       Date:  2014-05-08       Impact factor: 2.984

Review 8.  Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Authors:  Leonie Hennissen; Mireille J Bakker; Tobias Banaschewski; Sara Carucci; David Coghill; Marina Danckaerts; Ralf W Dittmann; Chris Hollis; Hanna Kovshoff; Suzanne McCarthy; Peter Nagy; Edmund Sonuga-Barke; Ian C K Wong; Alessandro Zuddas; Eric Rosenthal; Jan K Buitelaar
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

9.  Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study.

Authors:  Dan Edvinsson; Lisa Ekselius
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

10.  Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

Authors:  Samuele Cortese; Nicoletta Adamo; Cinzia Del Giovane; Christina Mohr-Jensen; Adrian J Hayes; Sara Carucci; Lauren Z Atkinson; Luca Tessari; Tobias Banaschewski; David Coghill; Chris Hollis; Emily Simonoff; Alessandro Zuddas; Corrado Barbui; Marianna Purgato; Hans-Christoph Steinhausen; Farhad Shokraneh; Jun Xia; Andrea Cipriani
Journal:  Lancet Psychiatry       Date:  2018-08-07       Impact factor: 27.083

View more
  9 in total

1.  Working Memory: From Neural Activity to the Sentient Mind.

Authors:  Russell J Jaffe; Christos Constantinidis
Journal:  Compr Physiol       Date:  2021-09-23       Impact factor: 8.915

Review 2.  Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Authors:  Fangyi Zhao; Ziqian Cheng; Jingjing Piao; Ranji Cui; Bingjin Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

3.  Enhanced Glial Reaction and Altered Neuronal Nitric Oxide Synthase are Implicated in Attention Deficit Hyperactivity Disorder.

Authors:  Peng Zhang; Huyue Fang; Chengjian Lou; Shan Ye; Guanghong Shen; Shijia Chen; Nashwa Amin; Benson O A Botchway; Marong Fang
Journal:  Front Cell Dev Biol       Date:  2022-06-21

4.  Perinatal Penicillin Exposure Affects Cortical Development and Sensory Processing.

Authors:  James Perna; Ju Lu; Brian Mullen; Taohui Liu; Michelle Tjia; Sydney Weiser; James Ackman; Yi Zuo
Journal:  Front Mol Neurosci       Date:  2021-12-22       Impact factor: 6.261

5.  Cell-Type Specific Deletion of CB2 Cannabinoid Receptors in Dopamine Neurons Induced Hyperactivity Phenotype: Possible Relevance to Attention-Deficit Hyperactivity Disorder.

Authors:  Ana Canseco-Alba; Branden Sanabria; Mariam Hammouda; Rollanda Bernadin; Marizel Mina; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Front Psychiatry       Date:  2022-02-08       Impact factor: 4.157

Review 6.  Mesocorticolimbic Dopamine Pathways Across Adolescence: Diversity in Development.

Authors:  Lauren M Reynolds; Cecilia Flores
Journal:  Front Neural Circuits       Date:  2021-09-08       Impact factor: 3.342

7.  A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure.

Authors:  Yasuhiro Ishihara; Tatsuya Honda; Nami Ishihara; Kaede Namba; Makiko Taketoshi; Yoko Tominaga; Mayumi Tsuji; Christoph F A Vogel; Takeshi Yamazaki; Kouichi Itoh; Takashi Tominaga
Journal:  J Neuroinflammation       Date:  2022-07-29       Impact factor: 9.587

Review 8.  Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies.

Authors:  Fabien Chauveau; Guillaume Becker; Hervé Boutin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-13       Impact factor: 9.236

9.  Dopamine adjusts the circadian gene expression of Per2 and Per3 in human dermal fibroblasts from ADHD patients.

Authors:  Frank Faltraco; Denise Palm; Adriana Uzoni; Lena Borchert; Frederick Simon; Oliver Tucha; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2021-07-18       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.